Document is current

Article History

Received: 15 July 2026

Accepted: 15 September 2026

First Online: 24 September 2026

Declarations

Ethics approval and consent to participate: The study was approved by the Ethics Committee of the Faculty of Medicine at LMU Munich (reference numbers: 17–569 and 19–022) and was conducted in accordance with the Declaration of Helsinki. All participants or their legally authorized representatives provided written informed consent to participate in the study and to undergo PET imaging.

Consent for publication: Written informed consent covered the use of anonymized imaging and clinical data for scientific publication where required. No directly identifiable individual participant data are presented.

Author information: These authors jointly supervised this work: Günter Höglinger, Nicolai Franzmeier, Matthias Brendel.

Competing interests: A.Dz. reports: research support: Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai, Novartis/AAA, Ariceum Therapeutics; Speaker Honoraria/Advisory Boards: Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis/AAA, Bayer Vital, Lilly, Peer View Institute for Medical Education, International Atomic Energy Agency: Stock: Siemens Healthineers, Lantheus Holdings, Structured therapeutics, Lilly; Patents: Patent for 18F-JK-PSMA- 7 (Patent No.: EP3765097A1; Date of patent: Jan. 20, 2021). MB is a member of the Neuroimaging Committee of the EANM. MB has received speaker honoraria from Roche, GE Healthcare, Iba, Miltenyi, and Life Molecular Imaging; has advised Life Molecular Imaging, MIAC, Cenos, and GE healthcare; and is currently on the advisory or imaging review boards of AC Immune and ZRO Imaging.